<span item_type="fundamental" item_id="d01cbed9740bf5d1a61b0b1d1e233019" counter_id="ST/US/BCTXW" env="prod"></span><span item_type="announcement" item_id="527937160123588481" env="prod"></span><p>EPS: As of FY2024, the actual value is USD -0.29.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Clinical Trials</strong>: Expenses increased to $15,833,879 in 2024 from $7,843,760 in 2023, primarily due to the expansion of the Bria-IMT™ trial and setup costs for the Bria-OTS™ trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li><li><strong>Pre-clinical Projects</strong>: Costs rose to $7,727,058 in 2024 from $3,787,673 in 2023, reflecting increased staffing and the addition of new pre-clinical programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the year ended July 31, 2024, was $4,791,466, compared to $20,302,394 in 2023. The decrease is attributed to a significant reduction in the fair value of the warrant liability.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Decreased to $6,152,269 in 2024 from $7,935,626 in 2023, due to lower insurance premiums, professional fees, and share-based compensation expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was $24,126,128 for the year ended July 31, 2024, compared to $23,744,860 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li><li><strong>Free Cash Flow</strong>: The overall cash and cash equivalents decreased by $20,389,003 during the year ended July 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Warrant Liability</strong>: The fair value of the warrant liability decreased significantly from $29,139,301 in 2023 to $1,096,036 in 2024, contributing to the reduced net loss.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company plans to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources. The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm"></span></li></ul>

BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM) | 10-K: FY2024 EPS: USD -0.29